Eli Lilly to Acquire Curevo, LimmaTech Biologics, and Vaccine Company for Up to $3.83 Billion to Expand Infectious Disease Prevention Portfolio

PharmaCircle DataMonitoringAnnouncement: On May 26, 2026, Eli Lilly and Company announced agreements to acquire Curevo, LimmaTech Biologics, and Vaccine Company, expanding its R&D footprint in the field of infectious diseases. This transaction continues Eli Lilly’s strategy of investing in differentiated technology platforms, aimed at addressing major health challenges.

For 150 years, Eli Lilly has remained dedicated to developing medicines to address the world’s most urgent health challenges. Infectious diseases, whether in their acute phase or through long-term health consequences stemming from primary infection, remain one of the leading causes of morbidity worldwide.

Daniel M. Skovronsky, Ph.D., Chief Scientific and Product Officer of Eli Lilly and President of Lilly Research Laboratories, stated, “This acquisition reflects the company’s clear strategy to prevent diseases at their source, rather than merely treating their consequences. Decades of research have confirmed that common infections are closely linked to the later development of neurological disorders, cancer, and infertility. As antimicrobial resistance increasingly undermines the clinical management of bacterial infections, vaccines have become a critical approach to preventing such infections. Integrating the technological platforms and R&D teams of these three companies with Eli Lilly’s global resources holds promise for reversing the passive stance in infectious disease prevention and control.”

Curevo’s core product candidate is amezosvatein, which isAn Adjuvanted Subunit Vaccine for the Prevention of Herpes Zoster in AdultsAlthough currently mainstream herpes zoster vaccines are effective, tolerability issues have led to low overall vaccination rates and hesitation regarding the second dose, leaving a large number of patients without adequate protection and unable to avoid the risks of herpes zoster and its long-term complications. Amezosvatein employs next-generation synthetic adjuvant technology to specifically address these pain points. In Phase II head-to-head clinical trials against the current standard of care, amezosvatein demonstrated immune responses at all primary efficacy endpoints comparable to the standard therapy, while reducing the incidence of adverse events affecting daily activities—such as fatigue, chills, and injection-site pain—by more than 50%. Studies have confirmed that herpes zoster increases the risk of stroke, and herpes zoster vaccination is associated with a reduced risk of dementia; therefore, vaccines with better tolerability can expand population coverage for herpes zoster prevention, thereby reducing the risk of related long-term diseases at the population level. Under the terms of the M&A agreement, the total consideration for Eli Lilly’s acquisition of Curevo may reach up to $1.5 billion in cash, including an upfront payment and subsequent payments upon the achievement of specific milestones.

LimmaTech Biologics specializes in the research and development of vaccines against bacterial pathogens, focusing on those with increasingly limited treatment options due to the growing threat of antimicrobial resistance, including Staphylococcus aureus, Neisseria gonorrhoeae, and Chlamydia trachomatis. The company’s proprietary technology platform targets virulence factors and superantigens, inducing broad-spectrum, durable immune responses against complex bacterial targets. ItsCore product LTB-SA7 is in Phase I clinical trials for the prevention of postoperative infections caused by the primary pathogen, Staphylococcus aureus.. The company’s preclinical pipeline also covers other bacterial pathogens, including those that are highly prevalent in women and can lead to infertility and other long-term sequelae of infection. A vaccine-centric prevention strategy holds promise for reversing the growing challenges in the clinical treatment of such diseases. Under the terms of the agreement, the total consideration for Eli Lilly’s acquisition of LimmaTech Biologics could reach up to $780 million in cash, comprising an upfront payment and additional payments upon the achievement of clinical and regulatory milestones.

Vaccine Company has independently developed in vivo nanoparticle technology, which enables the unique antigen presentation effect characteristic of virus-like particle (VLP) vaccines, inducing durable immune responses while circumventing the drawbacks of traditional VLP vaccine manufacturing processes, namely their complexity and high cost. The company possesses a preclinical product pipeline covering multiple viral pathogens, with its core project beingFive-Antigen Epstein-Barr Virus Vaccine, it has met the conditions for entering Phase I clinical trials. Studies have confirmed that Epstein-Barr virus (EBV) infection is closely associated with multiple sclerosis and various malignant tumors; therefore, this prophylactic vaccine can not only prevent acute infectious mononucleosis but also reduce the long-term risk of neurological diseases and malignancies following infection. According to the terms of the agreement, the total consideration for Eli Lilly’s acquisition of Vaccine Company could reach up to $1.55 billion in cash, including an upfront payment and subsequent payments upon the achievement of clinical and commercial milestones.

The transaction is subject to customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Upon closing, Eli Lilly will determine the accounting treatment for the transaction in accordance with Generally Accepted Accounting Principles (GAAP) and incorporate it into the company’s financial statements and earnings guidance. The aggregate maximum total value of the three acquisitions amounts to $3.83 billion, strengthening the company’s portfolio in vaccines for herpes zoster, bacterial pathogens, and Epstein-Barr virus (EBV).

References:

PharmRong Data;

https://www.sec.gov/Archives/edgar/data；

pharma.bcpmdata.com；

http://www.marketscreener.com；

https://www.businesswire.com；

www1.hkexnews.hk/；

https://biz.chosun.com/en/en-science；

https://www.koreabiomed.com/news；

Wait.